WASHINGTON, April 12, 2019 /PRNewswire/ -- The
Antimicrobials Working Group (AWG), a coalition of companies with
the mission to combat drug-resistant infections and spur
life-saving innovations, today announced that twelve of its member
companies will present data from their clinical and research
programs at the 29th annual meeting of the European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID
2019) to be held April 13 - 16 in
Amsterdam, Netherlands.
ECCMID is an annual scientific meeting that brings together the
leading experts in the fields of clinical microbiology, infectious
disease and infection control from across the globe to present and
discuss the latest developments in the laboratory and in the clinic
to advance research in a wide array of infectious diseases.
"AWG is excited that data from our member companies covering a
broad spectrum of infectious disease topics will be presented at
ECCMID 2019," said Evan Loh, M.D.,
President, Chief Operating Officer, and Chief Medical Officer of
Paratek Pharmaceuticals and Chairman of the AWG. "Representatives
from AWG companies will be participating in over 70 different oral
sessions and poster presentations, along with integrated symposiums
and industry panel discussions, showcasing developments in
antifungal, antibacterial, and non-traditional therapies. Their
efforts represent our coalition's sustained commitment to
antimicrobial innovation and our dedication to developing
life-saving treatments for patients in need."
The following AWG member companies will be presenting at ECCMID
2019: Amplyx Pharmaceuticals, Cidara Therapeutics, Contrafect
Corporation, Entasis Therapeutics, Iterum Therapeutics, Melinta
Therapeutics, Motif Bio, Nabriva Therapeutics, Paratek
Pharmaceuticals, SCYNEXIS, Summit Therapeutics, and VenatoRx
Pharmaceuticals.
For more information on AWG member company presentations and
access to specific abstracts, please visit: www.antimicrobialsworkinggroup.com/eccmid-2019/
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of fourteen antimicrobials companies: Amplyx
Pharmaceuticals, Aridis Pharmaceuticals, Cidara Therapeutics Inc.
(NASDAQ: CDTX), ContraFect Corporation (NASDAQ: CFRX), Entasis
Therapeutics Inc. (NASDAQ: ETTX), Iterum Therapeutics Ltd. (NASDAQ:
ITRM), Melinta Therapeutics Inc. (NASDAQ: MLNT), Motif Bio PLC
(AIM/NASDAQ: MTFB) , Nabriva Therapeutics US Inc. (NASDAQ: NBRV),
Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), Qpex Biopharma, Inc.,
SCYNEXIS Inc. (NASDAQ: SCYX), Summit Therapeutics plc (NASDAQ:
SMMT; AIM: SUMM), and VenatoRx Pharmaceuticals, Inc.
For more information, visit:
www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original
content:http://www.prnewswire.com/news-releases/antimicrobials-working-group-highlights-member-company-participation-at-the-29th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-300830990.html
SOURCE Antimicrobials Working Group (AWG)